SPRB

Spruce Biosciences, Inc. [SPRB] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

SPRB Stock Summary

Top 10 Correlated ETFs

SPRB


Top 10 Correlated Stocks

SPRB


In the News

01:01 29 Mar 2024 SPRB

Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know

Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

11:21 29 Mar 2024 SPRB

Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why

Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.

08:28 29 Mar 2024 SPRB

Why Is Spruce Biosciences (SPRB) Stock Down 78% Today?

Spruce Biosciences (NASDAQ: SPRB ) stock is falling hard on Thursday after the biopharmaceutical company posted two new updates for investors. The first big update that has investors in SPRB stock reeling are the results of a Phase 2b clinical trial of tildacerfont in adult patients with classic congenital adrenal hyperplasia ( CAH ).

04:05 29 Mar 2024 SPRB

Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 2:40 p.m. ET. Interested parties can access the live webcast here.

08:15 29 Mar 2024 SPRB

Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

04:00 29 Mar 2024 SPRB

Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET. Interested parties can access the live webcast here.

11:54 29 Mar 2024 SPRB

Best Penny Stocks To Buy? 3 To Watch With Targets Up To 400%

Analysts like these penny stocks but is it time to buy or not? The post Best Penny Stocks To Buy?

12:07 29 Mar 2024 SPRB

Penny Stocks To Buy? 4 Cheap Stocks To Watch Right Now

High volume penny stocks to watch right now. The post Penny Stocks To Buy?

04:05 29 Mar 2024 SPRB

Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #Tildacerfont--Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

08:27 29 Mar 2024 SPRB

Spruce Biosciences Stock (SPRB): Why The Price Jumped

The stock price of Spruce Biosciences Inc (NASDAQ: SPRB) increased by 13.48% in the most recent trading session. This is why it happened.

SPRB Financial details

Company Rating
Neutral
Market Cap
30.04M
Income
-47.64M
Revenue
10.09M
Book val./share
1.86
Cash/share
2.35
Dividend
-
Dividend %
-
Employees
31
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-2.29
Forward P/E
-0.78
PEG
0.66
P/S
15.21
P/B
1.28
P/C
0.33
P/FCF
-3.24
Quick Ratio
4.47
Current Ratio
4.59
Debt / Equity
0.05
LT Debt / Equity
0.02
-
-
EPS (TTM)
-1.25
EPS next Y
-1.01
EPS next Q
-0.29
EPS this Y
-35.42%
EPS next Y
-19.6%
EPS next 5Y
-124.8%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-6.05%
EPS Q/Q
-20%
-
-
-
-
SMA20
-85.96%
SMA50
-71.97%
SMA100
-32.73%
Inst Own
63.01%
Inst Trans
0.63%
ROA
-42%
ROE
-53%
ROC
-0.6%
Gross Margin
100%
Oper. Margin
-735%
Profit Margin
-665%
Payout
-
Shs Outstand
41.15M
Shs Float
23.43M
-
-
-
-
Target Price
-
52W Range
0.71-5.95
52W High
-
52W Low
-
RSI
23.21
Rel Volume
1.21
Avg Volume
1.11M
Volume
1.34M
Perf Week
5%
Perf Month
-83.96%
Perf Quarter
-62.22%
Perf Half Y
-65.38%
-
-
-
-
Beta
2.686
-
-
Volatility
0.03%, 2.14%
Prev Close
6.2%
Price
0.7859
Change
11.48%

SPRB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000.26
Net income per share
-1.45-5.01-1.83-1.92-1.24
Operating cash flow per share
-1.38-4.59-1.54-1.77-0.86
Free cash flow per share
-1.38-4.61-1.54-1.77-0.86
Cash per share
0.4326.233.813.362.5
Book value per share
-3.3524.944.772.911.99
Tangible book value per share
-3.3524.944.772.911.99
Share holders equity per share
-3.3524.944.772.911.99
Interest debt per share
0.491.080.290.280.11
Market cap
155.44M145.65M104.19M25.88M112.83M
Enterprise value
155.96M-5.37M67.61M7.57M21.1M
P/E ratio
-11.74-4.85-2.44-0.57-2.35
Price to sales ratio
000011.18
POCF ratio
-12.32-5.29-2.9-0.62-3.39
PFCF ratio
-12.32-5.28-2.9-0.62-3.39
P/B Ratio
-5.070.970.940.381.47
PTB ratio
-5.070.970.940.381.47
EV to sales
00002.09
Enterprise value over EBITDA
-11.990.18-1.61-0.17-0.41
EV to operating cash flow
-12.360.2-1.88-0.18-0.63
EV to free cash flow
-12.360.19-1.88-0.18-0.63
Earnings yield
-0.09-0.21-0.41-1.74-0.42
Free cash flow yield
-0.08-0.19-0.35-1.61-0.29
Debt to equity
-0.150.040.060.090.05
Debt to assets
0.950.040.050.070.03
Net debt to EBITDA
-0.045.170.870.41.77
Current ratio
1.0816.4310.366.724.18
Interest coverage
-201.65-91.07-121.93-112.58-107.65
Income quality
0.960.930.850.90.69
Dividend Yield
00000
Payout ratio
00-0.0100
Sales general and administrative to revenue
00001.25
Research and developement to revenue
00004.9
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.33-2.06-1.37-0.11-0.1
Stock based compensation to revenue
00000.46
Graham number
10.4553.031411.27.46
ROIC
0.51-0.19-0.36-0.61-0.64
Return on tangible assets
-2.82-0.18-0.34-0.53-0.46
Graham Net
-3.4323.983.162.631.79
Working capital
349K150.63M83.02M71.16M77.72M
Tangible asset value
-30.64M149.43M111.37M68.49M76.51M
Net current asset value
-30.68M146.94M76.78M66.45M74.75M
Invested capital
-0.150.040.060.090.05
Average receivables
00000
Average payables
2.09M2.75M3.23M2.12M2.38M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
57.12K12.98K2.7K1.21K17.37K
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.010.030.130.30.02
Inventory turnover
00000
ROE
0.43-0.2-0.38-0.66-0.63
Capex per share
0-0.01000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.060.050.080.07
Net income per share
-0.43-0.39-0.32-0.3-0.24
Operating cash flow per share
-0.5-0.370.05-0.3-0.27
Free cash flow per share
-0.5-0.370.05-0.3-0.27
Cash per share
3.363.722.972.652.35
Book value per share
2.913.392.382.11.86
Tangible book value per share
2.913.392.382.11.86
Share holders equity per share
2.913.392.382.11.86
Interest debt per share
0.270.180.130.120.09
Market cap
25.88M70.5M87.18M92.01M120.22M
Enterprise value
7.71M2.31M-5.03M-1.73M28.49M
P/E ratio
-0.63-1.41-1.7-1.86-3.02
Price to sales ratio
035.940.2729.9441.64
POCF ratio
-2.2-5.9843.74-7.5-10.73
PFCF ratio
-2.2-5.9843.74-7.49-10.73
P/B Ratio
0.380.650.91.081.57
PTB ratio
0.380.650.91.081.57
EV to sales
01.17-2.32-0.569.87
Enterprise value over EBITDA
-0.7-0.180.40.13-2.56
EV to operating cash flow
-0.66-0.2-2.520.14-2.54
EV to free cash flow
-0.66-0.2-2.520.14-2.54
Earnings yield
-0.39-0.18-0.15-0.13-0.08
Free cash flow yield
-0.45-0.170.02-0.13-0.09
Debt to equity
0.090.050.050.060.05
Debt to assets
0.070.040.040.040.03
Net debt to EBITDA
1.655.397.266.868.23
Current ratio
6.725.975.464.594.18
Interest coverage
-93.88-100.76-110.02114.77-105.32
Income quality
1.050.92-0.160.991.13
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
01.761.391.051.02
Research and developement to revenue
05.966.064.393.84
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.2500-0.410
Stock based compensation to revenue
00.540.560.370.42
Graham number
5.335.474.123.783.19
ROIC
-0.15-0.11-0.15-0.15-0.14
Return on tangible assets
-0.12-0.09-0.1-0.11-0.1
Graham Net
2.633.152.251.981.68
Working capital
71.16M114.24M101.4M86.95M77.72M
Tangible asset value
68.49M108M96.56M85.38M76.51M
Net current asset value
66.45M106.12M94.73M83.53M74.75M
Invested capital
0.090.050.050.060.05
Average receivables
07.5M7.5M00
Average payables
1.8M2.44M2.2M2.05M3.24M
Average inventory
01.7M1.7M00
Days sales outstanding
0687.37000
Days payables outstanding
994.884.03K1.15K16.69K18.74K
Days of inventory on hand
03.97K000
Receivables turnover
00.13000
Payables turnover
0.090.020.080.010
Inventory turnover
00.02000
ROE
-0.15-0.12-0.13-0.14-0.13
Capex per share
00000

SPRB Frequently Asked Questions

What is Spruce Biosciences, Inc. stock symbol ?

Spruce Biosciences, Inc. is a US stock , located in Daly city of Ca and trading under the symbol SPRB

What is Spruce Biosciences, Inc. stock quote today ?

Spruce Biosciences, Inc. stock price is $0.7859 today.

Is Spruce Biosciences, Inc. stock public?

Yes, Spruce Biosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap